2018
DOI: 10.1590/abd1806-4841.20187561
|View full text |Cite
|
Sign up to set email alerts
|

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0
5

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(13 citation statements)
references
References 6 publications
0
8
0
5
Order By: Relevance
“…Rituximab is an anti-CD20 monoclonal antibody approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, but it is used off-label for many other conditions [ 11 ]. Studies have shown its effectiveness in treating autoimmune skin disorders, such as pemphigus vulgaris, pemphigus foliaceus, vasculitis, SLE, and SCLE [ 12 ]. Currently, there are seventeen cases of cutaneous manifestation of SLE and eight cases with refractory SCLE treated with rituximab [ 12 , 13 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Rituximab is an anti-CD20 monoclonal antibody approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, but it is used off-label for many other conditions [ 11 ]. Studies have shown its effectiveness in treating autoimmune skin disorders, such as pemphigus vulgaris, pemphigus foliaceus, vasculitis, SLE, and SCLE [ 12 ]. Currently, there are seventeen cases of cutaneous manifestation of SLE and eight cases with refractory SCLE treated with rituximab [ 12 , 13 ].…”
Section: Discussionmentioning
confidence: 99%
“…Studies have shown its effectiveness in treating autoimmune skin disorders, such as pemphigus vulgaris, pemphigus foliaceus, vasculitis, SLE, and SCLE [ 12 ]. Currently, there are seventeen cases of cutaneous manifestation of SLE and eight cases with refractory SCLE treated with rituximab [ 12 , 13 ]. Of the eight refractory SCLE cases, seven showed effective results except one.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Aunque la fotoprotección, el tratamiento tópico y sistémico con corticoides y antipalúdicos se consideran un tratamiento de primera línea, un 50% de los pacientes se comportan de forma refractaria 10,11 . En estos pacientes las drogas inmunosupresoras, como azatioprina, metotrexato, micofenolato de mofetilo y ciclosporina, pueden constituir un tratamiento de segunda línea.…”
Section: Discussionunclassified
“…"High-dose" IVIG (2 g/kg BW/month) has been used successfully in autoimmune diseases. Several case reports and case series have shown positive effects in refractory CLE [87][88][89], but deterioration of skin lesions in SCLE and SLE has also been observed. One study treated 16 treatment-refractory patients with IVIG 500 mg/kg BW/day on four consecutive days up to a total of 2 g/kg BW/month over a period of three months.…”
Section: Intravenous Immunglobulinsmentioning
confidence: 99%